Abstract
The introduction of molecularly targeted therapies with tyrosine kinase inhibitors has revolutionized cancer therapy and has contributed to a steady decline in cancer-related mortality since the late 1990s. However, not only cardiac but also vascular toxicity has been reported for these agents, some as expected on-target effects (e.g., VEGF receptor inhibitors) and others as unanticipated events (e.g., BCR-Abl inhibitors). A sound understanding of these cardiovascular toxic effects is critical to advance mechanistic insight into vascular disease and clinical care. From a conceptual standpoint, there might be value in defining type I (permanent) and type II (transient) vascular toxicity. This review will focus on the tyrosine kinase inhibitors in current clinical use and their associated vascular side effects.
Original language | English (US) |
---|---|
Article number | 33 |
Journal | Current oncology reports |
Volume | 18 |
Issue number | 6 |
DOIs | |
State | Published - Jun 1 2016 |
Keywords
- Angina
- Cancer
- Cardiomyopathy
- Chemotherapy
- Endothelial dysfunction
- Myocardial infarction
- Stroke
- Thrombosis
- Vasospasm
ASJC Scopus subject areas
- Oncology